Kenneth Brown, MD
Psychiatry · Brentwood, NHNPI 1497798557
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $75,635 of the $94,319 with a category attached, or 80.2%. 16 manufacturers reported payments, led by Ironshore Pharmaceuticals Inc. at 54.9% of the total. 2025 is the largest year on record at $28,876, 7.7 times the $3,755 reported in 2019. Among psychiatry clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 328 payments — averaging $287.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ironshore Pharmaceuticals Inc.$52K
- Collegium Pharmaceutical, Inc.$28K
- AbbVie$8K
- Alkermes, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$810
- Otsuka America Pharmaceutical, Inc.$488
- plus $1K from 10 others
What the payments were for
- Speaking & faculty fees$75,63580%
- Travel & lodging$10,52011%
- Food & beverage$8,0489%
- Education$1160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ironshore Pharmaceuticals Inc. | 99 | $51,795 |
| Collegium Pharmaceutical, Inc. | 36 | $28,165 |
| AbbVie(2 entities) | 84 | $8,242 |
| Alkermes, Inc. | 16 | $3,346 |
| Teva Pharmaceuticals USA, Inc. | 17 | $810 |
| Otsuka America Pharmaceutical, Inc. | 21 | $488 |
| Sunovion Pharmaceuticals Inc. | 11 | $290 |
| Neurocrine Biosciences, Inc. | 6 | $231 |
| Lundbeck LLC | 9 | $224 |
| Johnson & Johnson | 9 | $197 |
| E.r. Squibb & Sons, L.L.C. | 6 | $172 |
| Supernus Pharmaceuticals, Inc. | 6 | $124 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $77 |
| Luye Pharma (USA) Ltd. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JORNAY PM$77,369
- VRAYLAR$7,072
- VIVITROL$2,916
- ARISTADA$407
- LATUDA$240
- AUSTEDO$221
- INGREZZA$117
- Austedo XR$103
- ARISTADA INITIO$102
How this compares
$94,319 in reported general payments places this provider in the 95th percentile of 166 psychiatry providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 59 | $87,234 |
| ProzacFluoxetine Hcl | 12 | $9,453 |
| Adderall XrDextroamphetamine/Amphetamine | 30 | $6,729 |
| TrintellixVortioxetine Hydrobromide | 12 | $6,062 |
| Jornay PmMethylphenidate Hcl | 11 | $4,987 |
| ViibrydVilazodone Hcl | 12 | $4,757 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 17 | $1,213 |
| Bupropion XlBupropion Hcl | 59 | $587 |
| Haloperidol | 12 | $428 |
| Escitalopram Oxalate | 43 | $326 |
| Duloxetine Hcl | 14 | $297 |
| Quetiapine Fumarate | 30 | $280 |
| Alprazolam ErAlprazolam | 22 | $202 |
| Buspirone Hcl | 36 | $168 |
| Clonidine Hcl | 27 | $102 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Viibryd | $8,242 | $91,99071 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $77 | $6,06212 claims |
| Ironshore Pharmaceuticals Inc.Jornay Pm | $51,795 | $4,98711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 166 psychiatry providers in New Hampshire.
Other psychiatry in Brentwood
- John MillerExeter$2.7M
- Stephen EllenNashua$1.4M
- Michael McNamaraManchester$754K
- Janet CarellaManchester$82K
- Robert CotesLebanon$64K
- Quentin TurnbullManchester$25K
- Paul LidstromLittleton$14K
- Juliette MadanLebanon$13K
- Wassfy HannaPortsmouth$10K
- Paul BelliveauExeter$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.